Newsletter
donate now

Search Results for: fludarabine – Page 3

ASH 2021: Dr. Stephan Stilgenbauer on Venetoclax-Based Time-Limited Combination Treatments for Chronic Lymphocytic Leukemia (CLL)

August 26, 2022

At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable residual disease (MRD) with the different treatments.

Impact of Low-Burden TP53 Mutations in the Management of CLL

July 6, 2022

Chronic Lymphocytic Leukemia (CLL) is a heterogeneous illness with a variable clinical course primarily determined by the disease’s underlying genetics, which is not the same for each affected individual. However, one gene that is highly important in predicting the natural history of CLL and response to chemoimmunotherapy is TP53, which resides on chromosome 17.

May 2022 CLL Bloodline

May 1, 2022

Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.  It will also provide news, help with the acronyms and

April 2022 CLL Bloodline

April 7, 2022

Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.  It will also provide news, help with the acronyms and

Chemotherapy

February 14, 2022

Chemotherapy Chemotherapy damages the cells’ DNA and non-specifically kills anything that grows quickly, such as cancer cells, but also skin, hair, gut, and normal blood cells. In CLL / SLL, common

February 2022 CLL Bloodline

February 4, 2022

Over the course of a year of monthly meetings, the CLL Bloodline will teach the BASICS needed to understand CLL, bring news, help with the acronyms and new vocabulary, and offer

Didn't find what you where looking for?

Try our advanced search page!
Search Now!